Ptc Therapeutics (PTCT) Change in Accured Expenses (2012 - 2026)

Ptc Therapeutics' Change in Accured Expenses history runs 15 years deep, the most recent figure standing at -$2.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 404.15% year-over-year to -$2.3 million; the TTM figure through Mar 2026 stood at -$19.2 million (down 457.22% YoY), while the FY2025 annual figure was -$17.4 million, down 247.05% from the prior year.
• Change in Accured Expenses was -$2.3 million for Q1 2026 at Ptc Therapeutics, down from $18.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $50.1 million in Q4 2023 to a low of -$43.2 million in Q3 2025.
• Historically, Change in Accured Expenses has averaged $2.1 million across 5 years, with a median of $5.7 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses plunged 1501.25% in 2022, then surged 917.86% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at -$6.1 million in 2022, then soared by 917.86% to $50.1 million in 2023, then sank by 66.94% to $16.6 million in 2024, then gained by 14.38% to $18.9 million in 2025, then sank by 112.19% to -$2.3 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.3 million (Q1 2026), $18.9 million (Q4 2025), and -$43.2 million (Q3 2025), per Business Quant data.